On April 1, 2026, bioAffinity Technologies, Inc. announced that its unit sales for the CyPath® Lung diagnostic in Q1 2026 grew by 146% compared to Q1 2025, exceeding internal projections and showing strong physician adoption.
AI Assistant
BIOAFFINITY TECHNOLOGIES INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.